

A Phase II, Open Label, Two Arm Study of Therapeutic Iobenguane (131I) as Single Agent or in Combination with Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects (OPTIMUM Trial) Protocol Number: MIBG 2014-01

Status: Recruiting

Eligibility Criteria

Conditions & Interventions

More Information

Description: This will be a Phase II, two-arm, nonrandomized, non-comparative, open-label study in participants ≥ 1 year of age with iobenguane avid, recurrent or progressive high-risk neuroblastoma. Participants not eligible for vorinostat treatment may receive 131I-MIBG as monotherapy.

Contact(s): Allison Fullenkamp - fulle631@umn.edu

Principal Investigator: Emily Greengard

IRB

Number: STUDY00005792

System ID: 24372

Thank you for choosing StudyFinder. Please visit <http://studyfinderstaging.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.